昊海生科(688366.SH):子公司肝素表面處理非球面人工晶狀體產品獲得醫療器械註冊批准
格隆匯11月30日丨昊海生科(688366.SH)公佈,公司全資子公司河南宇宙人工晶狀體研製有限公司(“河南宇宙”)於近日收到國家藥品監督管理局頒發的關於肝素表面處理非球面人工晶狀體產品的《中華人民共和國醫療器械註冊證》。
該產品是國產首個獲批的親水肝素表面處理非球面人工晶狀體。該產品由親水性丙烯酸材料製成,整個人工晶狀體表面經過肝素處理,增加了產品潤滑性,便於手術植入。臨牀研究表明,在安全性方面,肝素修飾人工晶狀體相比非肝素修飾人工晶狀體生物相容性好,臨牀使用術後炎性反應小。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.